# Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

> **NCT00094809** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 252 (actual)

## Conditions studied

- Colon Cancer
- Colorectal Cancer
- Rectal Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT00094809
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02-01
- **Primary completion:** 2006-05-19
- **Final completion:** 2008-01-23
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094809, "Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00094809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*